BamSEC and AlphaSense Join Forces
Learn More

Day One Biopharmaceuticals Inc. – Material Contracts

Formerly NASDAQ: DAWN

Material Contracts Filter

EX-10.6
from 10-K 16 pages Day One Biopharmaceuticals, Inc. Director Equity Deferral Plan
12/34/56
EX-10.1
from 8-K 28 pages Contingent Value Rights Agreement
12/34/56
EX-10.6
from 10-K 15 pages Material contract
12/34/56
EX-10.1
from 10-Q 76 pages Exclusive License Agreement by and Between Day One Biopharmaceuticals, Inc. and Ipsen Pharma Sas July 23, 2024
12/34/56
EX-10.2
from 10-Q 77 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Day One Biopharmaceuticals, Inc. if Publicly Disclosed. Exclusive License Agreement by and Between Mabcare Therapeutics (上海麦科思生物医药有限公司) and Day One Biopharmaceuticals, Inc. June 17, 2024
12/34/56
EX-10.1
from 10-Q 36 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Day One Biopharmaceuticals if Publicly Disclosed. Asset Purchase Agreement by and Between [*] and Day One Biopharmaceuticals, Inc. May 29, 2024
12/34/56
EX-10.2
from 8-K 20 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 3 pages [*] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to License Agreement for Raf
12/34/56
EX-10.1
from 10-Q 19 pages Office Sublease by and Between Aircraft Technical Publishers, a California Corporation, (“Sublandlord”) and Day One Biopharmaceuticals, Inc. (“Subtenant”) Dated as of April 1, 2022
12/34/56
EX-10.2
from 10-K 9 pages Change in Control and Severance Agreement
12/34/56
EX-10.9
from S-1/A 7 pages Re: Day One Biopharmaceuticals, Inc. – Employment Offer Dear Jeremy, Pursuant to Our Recent Discussions, I Am Pleased to Send You, on Behalf of Day One Biopharmaceuticals, Inc. (The “Company”), This Letter Agreement (The “Agreement”) Which Sets Forth the Terms of an Offer for Employment With the Company. 1. Position. Duties and Conditions Precedent
12/34/56
EX-10.3
from S-1/A 19 pages Day One Biopharmaceuticals, Inc. 2021 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 67 pages Day One Biopharmaceuticals, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10.8
from S-1 12 pages Share Exchange Agreement
12/34/56
EX-10.7
from S-1 48 pages Article 1 Definitions
12/34/56
EX-10.6
from S-1 38 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private and Confidential. License Agreement for Raf
12/34/56
EX-10.5
from S-1 61 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private and Confidential
12/34/56
EX-10.4
from S-1 55 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private and Confidential. Oyster Point Marina Plaza Office Lease of Suite 217 to Day One Therapeutics, Inc., a Delaware Corporation 395 Oyster Point Boulevard South San Francisco, Ca 94080 Oyster Point Marina Plaza Office Lease
12/34/56
EX-10.3
from S-1 19 pages Day One Biopharmaceuticals, Inc. 2021 Employee Stock Purchase Plan
12/34/56